Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by DAVIS, M. J.
Right arrow Articles by STANWORTH, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DAVIS, M. J.
Right arrow Articles by STANWORTH, D. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 British Society for Rheumatology

other

SULPHASALAZINE THERAPY IN ANKYLOSING SPONDYLITIS: ITS EFFECT ON DISEASE ACTIVITY, IMMUNOGLOBULIN A AND THE COMPLEX IMMUNOGLOBULIN A-ALPHA-1-ANTITRYPSIN

M. J. DAVIS*,1, P. T. DAWES*, E. BESWICK*, I. V. LEWIN{dagger} and D. R. STANWORTH{dagger}

*Staffordshire Rheumatology Centre, Haywood Hospital Burslem, Stoke-on-Trent ST6 TAG, UK
{dagger}Rheumatology and Allergy Research Unit, Department of Immunology, University of Birmingham Birmingham B15 2TJ, UK

Correspondence to: 1Correspondence to Dr. Davis.

Serum levels of immunoglobulin A (IgA) and the complex immunoglobulin A-{alpha}, antitrypsin (IgA-{alpha}1 AT) were measured at the commencement and after 3 months of a double-blind, placebo-controlled trial of sulphasalazine (SAS) in patients with active ankylosing spondylitis (AS). Twenty-eight patients were evaluated, 15 on sulphasalazine, 13 on placebo. Significant falls were seen in both IgA (p<0.01) and IgA-{alpha}1AT (p<0.001) in the actively treated patients. In addition, significant improvement in clinical and laboratory measures of disease were observed. It is concluded that SAS is effective in AS and modulates the immune response.

KEY WORDS: Sulphasalazine, Ankylosing spondylitis, Immunoglobulin A, Immunoglobulin A-{alpha}1anti-trypsin complex, Controlled trial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
D L MATTEY, N B NIXON, P T DAWES, L J SCOTT, G I RUSSELL;, K. IWANA, S. AOTSUKA;, and D. R STANWORTH
Measurement of IgA-alpha 1-antitrypsin complex in rheumatoid arthritis: A question of specificity?
Ann Rheum Dis, July 1, 1997; 56(7): 439 - 440.
[Full Text]

Home page
 LupusHome page
J.K. Lacki, T. Schochat, P. Leszczynski, S.H. Mackiewicz, and W. Muller
IgA-alpha-1-antitrypsin complex in systemic lupus erythematosus: preliminary report
Lupus, June 1, 1995; 4(3): 221 - 224.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.